PDG35 COST-EFFECTIVENESS ANALYSIS OF LOW-DOSE RIVAROXABAN PLUS ASPIRIN FOR THE PATIENTS WITH STABLE CARDIOVASCULAR DISEASE IN TAIWAN SETTING
May 1, 2019, 00:00
10.1016/j.jval.2019.04.714
https://www.valueinhealthjournal.com/article/S1098-3015(19)30906-4/fulltext
Title :
PDG35 COST-EFFECTIVENESS ANALYSIS OF LOW-DOSE RIVAROXABAN PLUS ASPIRIN FOR THE PATIENTS WITH STABLE CARDIOVASCULAR DISEASE IN TAIWAN SETTING
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30906-4&doi=10.1016/j.jval.2019.04.714
First page :
Section Title :
Open access? :
No
Section Order :
10310